Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.49 |
| ▸ | PLAU | P00749 | 5/20 | 0.49 |
| ▸ | PLAT | P00750 | 5/20 | 0.49 |
| ▸ | PLG | P00747 | 4/20 | 0.47 |
| ▸ | KLK8 | O60259 | 3/20 | 0.47 |
| ▸ | KLK4 | Q9Y5K2 | 3/20 | 0.47 |
| ▸ | KLK1 | P06870 | 3/20 | 0.47 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | KLK2 | P20151 | 2/20 | 0.47 |
| ▸ | MME | P08473 | 5/20 | 0.46 |
| ▸ | ECE1 | P42892 | 5/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23881669 | 0.91 | ATM (0.54) | F2PLAUPLATMMEECE1 | |
| SCHEMBL23881801 | 0.88 | ACE2 (0.48) | F2PLAUPLATMMEECE1 | |
| SCHEMBL23881729 | 0.88 | F2 (0.44) | F2PLAUPLATPLGKLK8 | |
| SCHEMBL28610449 | 0.87 | F2 (0.47) | F2PLAUPLATPLGKLK8 | |
| SCHEMBL23881822 | 0.87 | F2 (0.45) | F2PLAUPLATPLGKLK8 | |
| SCHEMBL23881692 | 0.86 | PTGES (0.46) | F2PLAUPLATPLGKLK8 | |
| SCHEMBL23881812 | 0.85 | ACE2 (0.52) | MMEECE1ELANEPRTN3ACE2 | |
| SCHEMBL23881703 | 0.85 | ECE1 (0.45) | F2PLAUPLATMMEECE1 | |
| SCHEMBL23881721 | 0.85 | ACE2 (0.46) | PLAUMMEECE1ACE2SMN1; SMN2 | |
| SCHEMBL23881906 | 0.84 | MME (0.52) | F2PLAUPLATPLGKLK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192907-B2 | Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same | QUANTUM GENOMICS (FR) | 2021-12-07 | — | — | US | disclosed |
| US-20210309678-A1 | AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Institut National de la Santé et de la Recherche Médicale (FR) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192907-B2 | Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same | ANPEP, DNPEP, ENPEP | F2 1153/4885PLAU 16/4885PLAT 63/4885 |
| US-20210309678-A1 | AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ANPEP, DNPEP, ENPEP | F2 1153/4885PLAU 16/4885PLAT 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.